Halozyme Therapeutics Inc. (HALO) announced Wednesday morning that it has entered into a global collaboration and license agreement with AbbVie (ABBV) to develop and commercialize products combining proprietary AbbVie compounds with Halozyme's ENHANZE platform.

Revance Therapeutics Inc. (RVNC) announced Wednesday morning that it plans to move forward with two clinical studies for RT001, a topical gel formulation of botulinum toxin type A. The company is planning a Phase 3 study for the treatment of adults with moderate to severe crow's feet lines and a Phase 2 study in adults with moderate to severe axillary hyperhidrosis, or excessive sweating.

Ardelyx Inc. (ARDX) announced Wednesday morning that it has entered into a termination agreement with AstraZeneca (AZN). Ardelyx will regain the rights to its portfolio of NHE3 inhibitors, including tenapanor. Ardelyx plans to accelerate the clinical development path for tenapanor in constipation-predominant irritable bowel syndrome by initiating a Phase 3 clinical program.

Vera Bradley Inc. (VRA) reported break-even first quarter earnings, on an adjusted basis, Wednesday morning. Analysts expected a profit of $0.02 per share. The company expects to report second quarter EPS of $0.10 to $0.13 and between $0.64 and $0.74 for the full year. The consensus estimates are for EPS of $0.17 and $0.84.

Quanex Building Products (NX) reported second quarter diluted EPS from continuing operations of $0.07, compared to the loss of $0.05 last year. The consensus estimate was for break-even results.

Stock Building Supply Holdings (STCK) announced Wednesday morning that it has signed a definitive merger agreement with Building Materials Holding to combine in an all-stock transaction.

The Wall Street Journal reported late Tuesday that Synchronoss Technologies Inc. (SNCR) is exploring a possible sale of the company. According to the report, a potential deal could be valued at over $2 billion.

G-III Apparel Group Ltd. (GIII) reported first quarter EPS of $0.15 after the bell Tuesday, up from $0.03 in the previous year. Analysts expected EPS of $0.07. Second quarter EPS is expected to be between $0.15 and $0.20. The consensus estimate is for EPS of $0.18. The company also increased its full year EPS forecast to between $2.66 and $2.76, from prior expectations of $2.53 to $2.63. Analysts are expecting EPS of $2.62.

According to media reports, Macy's Inc. (M) has been asked by several hedge funds to consider selling its real estate and then leasing it back.

Jefferies downgraded its rating on shares of Iron Mountain Inc. (IRM) Tuesday morning to "Underperform" to "Hold."

Regulus Therapeutics Inc. (RGLS) announced after the close Monday that Kleanthis G. Xanthopoulos, Ph.D. has resigned as President, CEO and as a member of its Board of Directors. Paul Grint, M.D. has been appointed as his replacement.

Dollar General Corp. (DG) reported first quarter EPS of $0.84 Tuesday morning, up from $0.72 a year ago. Analysts expected EPS of $0.81. Full year EPS is expected to be between $3.85 and $3.95. The consensus estimate is for EPS of $3.94.

LPL Financial Holdings Inc. (LPLA) announced after the bell Monday that it has named Matthew Audette as its new chief financial officer. Audette was the CFO at E*TRADE Financial Corporation.

Cracker Barrel Old Country Store (CBRL) reported third quarter adjusted EPS of $1.49 Tuesday morning, up from $1.23 last year. Analysts expected EPS of $1.37. Fourth quarter EPS is expected to be between $1.75 and $1.85. The consensus estimate is for EPS of $1.78. The company also increased its full year adjusted EPS forecast to between $6.60 and $6.70, from prior expectations of $6.40 to $6.50. Analysts are expecting EPS of $6.52.

PVH Corp. (PVH) reported first quarter adjusted EPS of $1.50 after the bell Monday, compared to $1.47 in the prior year period. Analysts expected EPS of $1.38. Full year 2015 adjusted EPS is expected to be between $6.85 and $6.95, compared to prior expectations of $6.75 to $6.90. The consensus estimate is for EPS of $6.86.

Zions Bancorporation (ZION) announced a corporate restructuring after the bell Monday. The company expects to achieve gross pre-tax cost savings of $120 million annually from operational expense initiatives by fiscal year 2017.

Boot Barn Holdings (BOOT) announced Monday morning that it has agreed to acquire Sheplers Inc. for $147 million in cash. The acquisition is expected to generate $6 million to $8 million of annual synergies and be immediately accretive to earnings.

HomeAway Inc. (AWAY) announced Monday morning that it has reached an agreement with KAYAK to display HomeAway vacation rentals on KAYAK sites by the end of the year.

SINA Corp. (SINA) announced Monday morning that it has entered into a subscription agreement with Charles Chao, its Chairman and Chief Executive Officer, for the issuance and sale of 11,000,000 newly issued ordinary shares of the Company to Mr. Chao. He will then pay $456 million in cash for the newly issued ordinary shares.

Momenta Pharmaceuticals Inc. (MNTA) announced Monday morning that it will present updated data from its Phase 1 trial of necuparanib in combination with nab-paclitaxel and gemcitabine in patients with advanced metastatic pancreatic cancer at the 2015 ASCO Annual Meeting.

Altera Corp. (ALTR) announced Monday morning that it has agreed to be acquired by Intel Corp. (INTC) for $54 per share in an all-cash transaction, or approximately $16.7 billion.

Ignyta Inc. (RXDX) announced Monday morning that interim results from its two Phase 1 clinical trials of entrectinib were presented in poster presentations, including a poster discussion, at the 2015 ASCO meeting.

ImmunoGen Inc. (IMGN) announced Saturday that it presented results from an ongoing Phase 1 trial of mirvetuximab soravtansine at the ASCO meeting. An objective response rate of 53% was observed in patients with folate-receptor alpha (FRa)-positive platinum-resistant ovarian cancer. The company is preparing to initiate a Phase 2 trial in late 2015.

OM Group Inc. (OMG) announced Monday morning that it has agreed to be acquired by funds managed by affiliates of Apollo Global Management LLC (APO) for $34.00 per share in cash.

Altera Corp. (ALTR) is gaining 6 percent to $51.86 based on the news that Intel Corp. (INTC) has agreed to buy the company for $54 per share in cash, valuing the company at about $16.7 billion. INTC is down four tenths of a percent to $34.32.

The New York Post reported Friday morning that Altera Corp. (ALTR) is close to a deal to be acquired by Intel (INTC) for approximately $15 billion.

Rosetta Stone Inc. (RST) announced Friday morning that its Board of Directors has received an expression of interest from RDG Capital Fund Management.

Bristol-Myers Squibb (BMY) announced Friday afternoon that Opdivo demonstrated superior overall survival versus standard of care in its Phase 3 study of patients with advanced, non-squamous non-small cell lung cancer. Opdivo decreased risk of progression or death by 27% compared to standard of care.

Greif Inc. (GEF) announced after the bell Thursday that it now expects to report full year adjusted EPS of $1.65 to $1.75. Prior expectations had been for EPS of $2.25 to $2.35. The consensus estimate is for EPS of $2.23.

GameStop Corp. (GME) reported first quarter EPS of $0.68 after the bell Thursday, compared to $0.59 in the prior year period. Analysts expected EPS of $0.59. The company expects to report second quarter EPS of $0.21 to $0.25. GameStop also raised its full year EPS guidance to between $3.63 and $3.83, from prior guidance of $3.60 to $3.80. The consensus estimates are for EPS of $0.21 and $3.83.